Wyeth Korea to launch Enbrel at year-end

Published: 2003-10-22 07:00:00

Updated: 2003-10-22 07:00:00

Wyeth Korea announced the Korea Food and Drug Administration has recently approved Enbrel (entanercept), TNF (tumor necrosis factor) inhibitor for the treatment of rheumatoid arthritis drug, as local trials last March was successfully completed in patients with rheumatoid arthritis.

Enbrel imp...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK